| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | April 10, 2025 9:00 A.M. |
| Form: | S-1 | ||||||
| |||||||
Save time and jump to the most important pieces.
Northstrive Biosciences received preliminary meeting responses from the FDA regarding Northstrive's nonclinical studies and clinical development plans for EL-22, administered in combination with GLP-1 receptor agonists.Northstrive believes the FDA responses encourage a path forward for filing an IND application to conduct a Phase 2 clinical trial in overweight or obese patients.EL-22 is leveraging a myostatin-engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. NEWPORT BEACH, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Northstrive Biosciences Inc. ("Northstrive"), a subsidiary of PMGC Ho
NEWPORT BEACH, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:PMGC) (the "Company," "PMGC," "we," or "us"), a diversified public holding company, is pleased to announce the signing of a non-binding Letter of Intent ("LOI") to acquire a U.S.-based, cash-flow positive information technology ("IT") custom packaging company. About the Target Company Founded in 2011 and headquartered in Southern California, the Target is a well-established provider of custom packaging solutions for IT products, serving over 300 commercial clients—including data centers, technology manufacturers, and IT service providers. With close to 15 years of uninterrupted operations, the compan
Northstrive Biosciences and Yuva Biosciences' collaboration will leverage MitoNova™, YuvaBio's proprietary mitochondrial science-focused artificial intelligence platform, to discover and develop novel pharmaceutical treatments for obesity, type 2 diabetes and other cardiometabolic conditions.Northstrive and Yuva Biosciences will compile a library of small molecule candidates that promote mitochondrial health and target the root cause of aging at the cellular level. NEWPORT BEACH, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- Northstrive Biosciences Inc. ("Northstrive" or "Northstrive Biosciences"), a subsidiary of PMGC Holdings Inc. (NASDAQ:ELAB) ("PMGC," "we," or "our"), announced today th
SC 13G - Elevai Labs Inc. (0001840563) (Subject)
SC 13G - Elevai Labs Inc. (0001840563) (Subject)
SC 13G - Elevai Labs Inc. (0001840563) (Subject)
8-K - PMGC Holdings Inc. (0001840563) (Filer)
8-K - PMGC Holdings Inc. (0001840563) (Filer)
424B5 - PMGC Holdings Inc. (0001840563) (Filer)
NEWPORT BEACH, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (the "Company" or "PMGC," "our," or "we") (NASDAQ:ELAB), a diversified holding company, is proud to announce its annual sponsorship of TCA Venture Group's ("TCA") Orange County network for 2025. As a Southern California Network Sponsor, PMGC is actively pursuing investments and M&A opportunities to strengthen its portfolio while fostering local business growth and expanding its market presence. TCA Venture Group (formerly known as Tech Coast Angels) is one of the largest and most active angel investor networks in the United States. With a history spanning over 25 years, TCA has been instrumental in funding early-s
Professor of Medicine at the University of California, Los Angeles (UCLA), where he serves as Director of the UCLA Metabolism Research Theme.Over 180 publications in the field of obesity & metabolism, along with multiple NIH-funded projects as Principal Investigator.Dr. Shirihai is a renowned researcher regularly invited as a keynote speaker at annual scientific conferences and has consulted for Johnson & Johnson, Bayer, AstraZeneca and Pfizer, among other healthcare companies. NEWPORT BEACH, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ:ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics, announced the appointment of Orian Shirihai, MD, PhD, t
NEWPORT BEACH, Calif., June 14, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ:ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics, announced the formation of a new Scientific Advisory Board to support the advancement of EL-22, a first-in-class engineered probiotic approach, to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. "We are honored to be forming a Scientific Advisory Board with renowned members that possess deep and complementary knowledge in metabolic diseases, obesity, weight management, muscle preservation and physical function in addition to significant experience in clinical
Agreement adds two drug candidates to product pipeline consisting of (i) "EL-22", a clinical stage engineered probiotic expressing myostatin, and (ii) "EL-32", a preclinical engineered probiotic expressing dual myostatin & activin-A.Exclusive license covers global rights excluding South Korea.Clinical and preclinical data supports advancing EL-22, a novel investigational myostatin asset for the treatment of obesity for an investigational new drug "IND" application in 2025. EL-22 has demonstrated significant increase in body weight and restored muscle damage in preclinical mouse models, suggesting potential as a combination to glucagon-like peptide-1 "GLP-1" products to treat obesity. NEWPOR
4 - PMGC Holdings Inc. (0001840563) (Issuer)
3/A - PMGC Holdings Inc. (0001840563) (Issuer)
4 - PMGC Holdings Inc. (0001840563) (Issuer)